SCHEMBL4228017

SCHEMBL4228017

O=C(O)c1ccc(-c2cccc(O)c2)cc1Nc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.54
AKR1C2 P52895 2/20 0.54
HCAR2 Q8TDS4 1/20 0.53
MAPT P10636 1/20 0.53
GFER P55789 1/20 0.53
NGLY1 Q96IV0 1/20 0.53
FABP4 P15090 1/20 0.51
ACLY P53396 3/20 0.49
ACMSD Q8TDX5 2/20 0.49
HNF4A P41235 1/20 0.49
CYP3A4 P08684 2/20 0.49
TSHR P16473 1/20 0.49
GRIK1 P39086 2/20 0.48
XDH P47989 1/20 0.48
SLC22A12 Q96S37 1/20 0.48
FTO Q9C0B1 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.47
SIRT1 Q96EB6 1/20 0.47
MCL1 Q07820 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222898 0.94 AKR1C3 (0.51) AKR1C3AKR1C2HCAR2ACLYCYP3A4
SCHEMBL4212934 0.93 SIRT2 (0.52) AKR1C3AKR1C2HCAR2ACLYACMSD
SCHEMBL4223119 0.89 AKR1C3 (0.60) AKR1C3AKR1C2MAPTGFERNGLY1
SCHEMBL4223004 0.89 XDH (0.50) AKR1C3AKR1C2HCAR2MAPTACLY
SCHEMBL4221820 0.87 HNF4A (0.54) AKR1C3AKR1C2MAPTGFERNGLY1
SCHEMBL4223666 0.86 SIRT2 (0.61) AKR1C3AKR1C2MAPTGFERNGLY1
SCHEMBL4222990 0.86 ACLY (0.59) AKR1C3AKR1C2MAPTGFERNGLY1
SCHEMBL4209169 0.85 GRIK1 (0.58) AKR1C3AKR1C2HCAR2GFERACLY
SCHEMBL4211160 0.84 ACLY (0.60) AKR1C3AKR1C2HCAR2MAPTGFER
SCHEMBL4222643 0.83 FABP4 (0.56) AKR1C3AKR1C2HCAR2FABP4ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 AKR1C3 105/4885AKR1C2 287/4885HCAR2 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.